Pharmacological interventions that attenuate CRM1 activity reduce neuronal death and restore nucleocytoplasmic transport in either a model of Huntington's disease [39], a model of amyotrophic lateral sclerosis and frontotemporal dementia [42], and a Drosophila model of tauopathies [40]. Here, XPO1 is linked to juvenile Huntington disease.